Newswise BIRMINGHAM, Ala. Biomedical engineering researchers will attack two banes of cardiovascular disease heart failure after heart attacks and the scourge of resistant high blood pressure with $4.8 million in National Institutes of Health grants that begin this fall.
One sign of the clinical significance of this research by the University of Alabama at Birmingham investigators are the percentile scores that Jianyi Jay Zhang, M.D., Ph.D., and Gangjian Qin, M.D., received in those two NIH grant applications.
Zhangs plan to dissect the mechanisms of electromechanical integration of a human heart-muscle patch to aid survival and stability of the patch garnered a 1 percentile score, the highest possible. Qins plan to dissect a novel molecular pathway in endothelial cells of arteries that appears to regulate contractile function and blood pressure has significant potential to improve human health from the disease and death caused by high blood pressure, NIH reviewers said, and Qin received a 2 percentile score.
Zhang, chair and professor of the UAB Department of Biomedical Engineering and holder of the T. Michael and Gillian Goodrich Endowed Chair of Engineering Leadership, will receive $2.5 million over four years. Qin, professor of biomedical engineering and director of the Molecular Cardiology Program, will receive $2.3 million over four years.
Zhang came to UAB in 2015 from the University of Minnesota Medical School with the goal of moving his work with engineered heart patches into human use within seven years. As chair of Biomedical Engineering, a joint department of the UAB School of Medicine and the UAB School of Engineering, Zhang has recruited top researchers, and he also was awarded $11 million of NIH funding in 2016 $8 million of which is shared in collaborations with University of Wisconsin and Duke University researchers.
One of the recent recruits to biomedical engineering is Qin, who serendipitously discovered a novel and fascinating line of research that may lead to new drugs for treatment-resistant high blood pressure, where existing blood pressure drugs are ineffective. People with resistant high blood pressure have increased risk of strokes, heart attacks, heart failure and arterial aneurysms, and high blood pressure is a leading cause of chronic kidney failure. Even moderately elevated arterial blood pressure shortens life expectancy.
At the time, Qin was interested in the often fatal heart failure that occurs months or years after heart attacks. He reasoned that growth of new blood vessels into the damaged heart tissue of the left ventricle could be boosted by altering the amounts of cell-cycle regulators in the E2F family of transcription factors, to speed division of cells in the endothelial tissue of arteries.
When he deleted one of the eight E2Fs that are found in mice and humans E2F2 it had no effect on cell growth. But unexpectedly, we found a striking function, Qin said. If you delete E2F2, the vessel is more contractile. It becomes rigid and hard, and this contributes to high blood pressure.
So we had a question: How does E2F2 interact with other molecules to regulate blood pressure? Qin did pull-down experiments with E2F2, where other proteins are flowed past tethered E2F2 molecules to see if any would bind. He found that a kinase enzyme called Sam68 did bind to the transcription factor.
When he knocked out the gene for Sam68 in mice, they had low blood pressure.
Ultimately, a series of experiments in Qins lab and observations of other laboratories suggested a previously unknown mechanism of blood pressure control that involves E2F2/Sam68 and the expression of endothelial converting enzyme 1b. ECE-1b affects the levels of peptides that constrict blood vessels and raise blood pressure. Dysregulation of this pathway may contribute to blood pressure disorders, especially hypertension.
Despite a strong correlation, the E2F2/Sam68-ECE-1b pathway has not explicitly been linked to blood pressure regulation, and the mechanisms of how Sam68/E2F2 signaling regulates ECE-1b expression and blood vessel function remain uncharacterized.
Qin will use his new grant to search for the link to blood pressure regulation and characterize the mechanisms. His research could provide the missing links between the results of large-scale genomewide association studies of human high blood pressure and its pathogenesis namely how dysregulation leads to refractory hypertension.
Detailed knowledge of those steps would offer new targets for potential new drugs, which are especially needed to prevent or treat resistant hypertension.
Qin says he was attracted to UAB by the strong focus of clinicians and basic scientists on solving the clinical problem of hypertension, as well as the depth and breadth of cardiovascular disease research in biomedical engineering, the UAB Department of Pathology and the UAB Division of Cardiovascular Disease. He also has great interest in Zhangs research, where Qins past work in stem cell biology and cardiovascular science can contribute.
As measured by NIH funding, the UAB Department of Biomedical Engineering is the fourth-ranked biomedical engineering department among all departments that are jointly led by schools of medicine and engineering, according to the 2016 Blue Ridge NIH database.
The joint biomedical engineering departments ahead of UAB are at Stanford University, Johns Hopkins University, and Oregon Health and Science University. Those trailing UAB in the funding ranking are at the University of North Carolina-Chapel Hill, Emory University, University of Virginia, Case Western Reserve University, University of Colorado-Denver, University of Rochester, the University of Illinois-Chicago, Wake Forest University Health Sciences and State University of New York-Stony Brook.
Read more from the original source:
New Biomedical Engineering Grants Aim at Heart Failure and Resistant High Blood Pressure - Newswise (press release)
- Hannah just thought she was being clumsy, but her bruises were a sign she needed to see her doctor - Daily Mail - October 27th, 2023
- Brent Rutemiller's Cancer In Early Remission After 42 Weeks of Chemotherapy and Stem Cell Transplant - Swimming World Magazine - May 20th, 2022
- Other Notable Health Studies & Research From May 17, 2022 - Study Finds - May 20th, 2022
- Clinton County Relay For Life holds annual event in Riverview Park - Lock Haven Express - May 20th, 2022
- Illinois Is Being Invaded By Worms That Jump A Foot In The Air - 1440wrok.com - May 20th, 2022
- Moderna, J&J COVID Booster Shots Near Authorization. Here's What to Know - NBC Chicago - October 26th, 2021
- GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF- R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research -... - October 26th, 2021
- Merck Provides Update on KEYTRUDA (pembrolizumab) Indication in Third-Line Gastric Cancer in the US - Business Wire - July 6th, 2021
- Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene - GlobeNewswire - July 6th, 2021
- New global guidelines for stem cell research aim to drive discussions, not lay down the law - The Conversation AU - May 27th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 27th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 27th, 2021
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 27th, 2021
- OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for... - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Opdivo in Combination with Cabometyx Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced RCC -... - February 14th, 2021
- Astellas and Seagen Announce Presentation of Results from PADCEV (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced... - February 14th, 2021
- [Full text] Loganin Attenuates Septic Acute Renal Injury with the Participation of | DDDT - Dove Medical Press - February 14th, 2021
- [Full text] Encephalopathy Induced by Preventive Administration of Acyclovir in a | IJGM - Dove Medical Press - February 14th, 2021
- Joint inflammation: Causes, treatment, and symptoms - Medical News Today - February 14th, 2021
- Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity - PRNewswire - February 3rd, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 3rd, 2021
- Mini kidneys bioprinted in the lab - Lab + Life Scientist - December 4th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - December 4th, 2020
- News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon's graft-versus-host drug -... - December 4th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - December 4th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 11th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 11th, 2020
- Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 - Investing News Network - November 11th, 2020
- The great reset: new danger on the horizon - Amandala - November 11th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 11th, 2020
- COVID Drug Given to Trump Developed From Aborted Fetus Cells - Quint Fit - October 10th, 2020
- Lars Jaeger: The Future is Veggie, With 3D Printing - finews.asia - October 10th, 2020
- Laid off from ImmunoGen, an ex-Genzyme and Shire exec heads to an ARCH upstart - Endpoints News - October 10th, 2020
- 5 Deadly Pre-existing Conditions You Could Have Due To COVID-19 - Brumpost - Brumpost - October 10th, 2020
- The Crypto Daily Movers and Shakers October 10th, 2020 - Sports Grind Entertainment - October 10th, 2020
- Coronavirus Tracker: Bexar Co. cases surpass 59,000; Texas hospitalizations trending in the wrong direction - KENS5.com - October 10th, 2020
- Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million - Business Wire - September 24th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 15th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - Business Wire - September 15th, 2020
- Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma - OncLive - September 9th, 2020
- Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients - GlobeNewswire - September 9th, 2020
- ASX Biotechs Surfing The Covid Story - FN Arena News - August 16th, 2020
- Merck and Eisai Receive Complete Response Letter for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination as First-Line Treatment for... - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma - Business... - July 10th, 2020
- Coronavirus PPP Loans In Livingston: Where The Money Went - Livingston, NJ Patch - July 9th, 2020
- Stem Cell Therapy For Kidney Failure. Learn More Now ... - July 7th, 2020
- Anemia in chronic kidney disease - kidneyfund.org - July 7th, 2020
- Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead - July 7th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer -... - June 30th, 2020
- R3 International Offering Stem Cell Therapy Program for Anti Aging in Mexico - PR Web - June 30th, 2020
- Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse - June 30th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that... - June 25th, 2020
- Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System - Business Wire - June 25th, 2020
- First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times - May 27th, 2020
- Scientists generate millions of mature human cells, far more than have ever been produced - UB News Center - May 20th, 2020
- Heres The Reason Why Scientists Are Growing Human Cells In Mouse Embryo - Medical Daily - May 20th, 2020
- Cell therapies trial planned for COVID-19 - Mirage News - May 5th, 2020
- New Study Finds That Wearing Contact Lenses Doesn't Increase Risk of COVID-19 Infection - HealthDay Coronavirus Liveblog - April 26th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 15th, 2020
- Stem Cells and Chronic Kidney Disease | Mayo Clinic Center ... - April 11th, 2020
- Kidney Failure | Stem Cell Treatment in Tijuana Mexico - April 11th, 2020
- MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND... - April 11th, 2020
- Merck Receives Priority Review from FDA for Second Application for KEYTRUDA (pembrolizumab) Based on Biomarker, Regardless of Tumor Type - Benzinga - April 11th, 2020
- A coronavirus vaccine is being developed in record time. But dont expect that technology to speed up flu vaccines yet. - Columbia Daily Herald - April 7th, 2020
- Researchers test drug that stops early stages of COVID-19 - Open Access Government - April 7th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- Made-in-space organs could soon be reality - ETHealthworld.com - March 13th, 2020
- What Is the Coronavirus? - WIRED - March 6th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 25th, 2020
- Coronavirus: Doctors try 3,000-year-old Traditional Chinese Medicine (TCM) to treat the virus - Times of India - February 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for... - February 14th, 2020
- Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy... - February 14th, 2020
- Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha - February 10th, 2020
- Cambridge Science Festival showcases new research at the forefront of healthcare and medicine - Cambridge Network - February 10th, 2020
- Anemia: Causes, symptoms and treatment - Livescience.com - February 8th, 2020
- 4 Crazy but Effective Ways to Save More Money This Year - Nasdaq - February 4th, 2020
- BAME lives to be saved as new organ donation law rolls out - Keep the Faith - January 15th, 2020
- HIV drug resistance an emerging threat, expert warns - DAWN.com - January 10th, 2020
- A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org - January 10th, 2020